ES2068791T1 - Metodos y acido desoxirribonucleico para la preparacion de proteina de factor de tejido. - Google Patents

Metodos y acido desoxirribonucleico para la preparacion de proteina de factor de tejido.

Info

Publication number
ES2068791T1
ES2068791T1 ES88301190T ES88301190T ES2068791T1 ES 2068791 T1 ES2068791 T1 ES 2068791T1 ES 88301190 T ES88301190 T ES 88301190T ES 88301190 T ES88301190 T ES 88301190T ES 2068791 T1 ES2068791 T1 ES 2068791T1
Authority
ES
Spain
Prior art keywords
tissue factor
factor protein
methods
preparation
deoxyribonucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES88301190T
Other languages
English (en)
Other versions
ES2068791T3 (es
ES2068791T5 (es
Inventor
Richard Mark Lawn
Karen Lynne Wion
Gorden Allen Vehar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27359940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2068791(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ES2068791T1 publication Critical patent/ES2068791T1/es
Publication of ES2068791T3 publication Critical patent/ES2068791T3/es
Application granted granted Critical
Publication of ES2068791T5 publication Critical patent/ES2068791T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

AISLADOS DE DNA QUE CODIFICAN PARA PROTEINA FACTOR DE TEJIDOS Y SUS DERIVADOS, Y METODOS PARA OBTENER TAL DNA Y PRODUCIR PROTEINA FACTOR DE TEJIDOS Y SUS DERIVADOS UTILIZANDO SISTEMAS DE EXPRESION RECOMBINANTES PARA USO EN COMPOSICIONES TERAPEUTICAS PARA EL TRATAMIENTO DE DESORDENES DE COAGULACION.
ES88301190T 1987-02-12 1988-02-12 Metodos y acido desoxirribonucleico para la preparacion de la proteina del factor tisular. Expired - Lifetime ES2068791T5 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US1374387A 1987-02-12 1987-02-12
US13743 1987-02-12
US3540987A 1987-04-07 1987-04-07
US35409 1987-04-07
US15269888A 1988-02-05 1988-02-05
US152698 1988-02-05

Publications (3)

Publication Number Publication Date
ES2068791T1 true ES2068791T1 (es) 1995-05-01
ES2068791T3 ES2068791T3 (es) 1997-10-01
ES2068791T5 ES2068791T5 (es) 2004-12-16

Family

ID=27359940

Family Applications (2)

Application Number Title Priority Date Filing Date
ES88301190T Expired - Lifetime ES2068791T5 (es) 1987-02-12 1988-02-12 Metodos y acido desoxirribonucleico para la preparacion de la proteina del factor tisular.
ES97200009T Expired - Lifetime ES2244989T3 (es) 1987-02-12 1988-02-12 Metodos y acido desoxirribonucleico para la preparacion de la proteina del factor tisular.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES97200009T Expired - Lifetime ES2244989T3 (es) 1987-02-12 1988-02-12 Metodos y acido desoxirribonucleico para la preparacion de la proteina del factor tisular.

Country Status (10)

Country Link
EP (2) EP0787802B1 (es)
JP (1) JP2869920B2 (es)
AT (2) ATE298800T1 (es)
AU (1) AU617302B2 (es)
DE (3) DE3856580T2 (es)
ES (2) ES2068791T5 (es)
GR (1) GR3024263T3 (es)
IE (1) IE81149B1 (es)
IL (1) IL85411A (es)
NZ (1) NZ223506A (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7084251B1 (en) 1987-02-12 2006-08-01 Genentech, Inc. Methods and Deoxyribonucleic acid for the preparation of tissue factor protein
US6994988B1 (en) 1987-02-12 2006-02-07 Genetech, Inc. Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
JPH02501263A (ja) * 1987-06-12 1990-05-10 マウント　サイナイ　スクール　オブ　メディシン　オブ　ザ　シティー　ユニバーシティー　オブ　ニューヨーク ヒトの組織因子のクローニングと形質発現
IL87172A (en) * 1987-07-23 1994-12-29 Univ Washington A method of inhibiting the isolation of a purer tissue factor
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
NO892506L (no) * 1988-06-17 1989-12-18 Sinai School Medicine Kloning og ekspresjon av human vevsfaktor.
ES2176174T3 (es) * 1988-12-22 2002-12-01 Genentech Inc Procedimiento de preparacion de polipeptidos solubles en agua.
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
WO1990008956A1 (fr) * 1989-02-02 1990-08-09 Teijin Limited Detection d'activateur de facteur tissulaire humain
US5314695A (en) † 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
DE4240103A1 (de) * 1992-05-26 1993-12-02 Behringwerke Ag Verfahren zur Inaktivierung von Viren in Präparationen von Proteinen
ATE202633T1 (de) * 1994-04-28 2001-07-15 Dade Behring Inc Kalibrator für prothrombin-zeit-assays
US5696086A (en) * 1994-11-03 1997-12-09 Genentech, Inc. Methods and kits using macrophage stimulating protein
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
CN100333796C (zh) 1997-01-22 2007-08-29 德克萨斯州立大学董事会 凝血和肿瘤治疗的组织因子及其组合物
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6642433B1 (en) 1997-05-15 2003-11-04 Trillium Therapeutics Inc. Fgl-2 knockout mice
EP0975361B1 (en) * 1997-05-15 2006-09-20 Trillium Therapeutics Inc. Methods of modulating immune coagulation
DE19749259A1 (de) 1997-11-07 1999-05-12 Dade Behring Marburg Gmbh Verfahren zur Herstellung von funktionalem rekombinantem Gewebsfaktor
CA2331789C (en) 1998-07-13 2013-09-10 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
DK1222854T3 (da) 1999-10-01 2011-03-14 Chugai Pharmaceutical Co Ltd Forebyggelse og behandling af sygdomme forbundet med blodkoagulering
DE60030323T2 (de) 1999-12-24 2007-10-11 Genentech, Inc., South San Francisco Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
EP1757701A1 (en) 1999-12-24 2007-02-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
EP1409713B1 (en) 2001-07-03 2013-03-20 Oklahoma Medical Research Foundation Assay for measuring factor viia-antithrombin complexes
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
EP1774001B1 (en) * 2004-06-25 2012-08-22 Altor BioScience Corporation Mammalian Tissue Factor obtained from plants and applications of the same
WO2008033890A2 (en) 2006-09-12 2008-03-20 Beth Israel Deaconess Medical Center, Inc. Compositions containing alpha-1-antitrypsin and methods for use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663283A (en) 1980-03-24 1987-05-05 Genentech, Inc. Method of altering double-stranded DNA
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
NZ209307A (en) * 1983-08-30 1990-07-26 Genentech Inc Diagnostic product: antigenic peptide produced by recombinant dna techniques
NZ209308A (en) 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US4680262A (en) 1984-10-05 1987-07-14 Genentech, Inc. Periplasmic protein recovery
JPH02501263A (ja) * 1987-06-12 1990-05-10 マウント　サイナイ　スクール　オブ　メディシン　オブ　ザ　シティー　ユニバーシティー　オブ　ニューヨーク ヒトの組織因子のクローニングと形質発現
DE10124940A1 (de) 2001-05-21 2002-11-28 Philips Corp Intellectual Pty Netzwerk mit logischen Kanälen und Transportkanälen

Also Published As

Publication number Publication date
EP0787802B1 (en) 2005-06-29
GR3024263T3 (en) 1997-10-31
ES2068791T3 (es) 1997-10-01
IL85411A0 (en) 1988-07-31
EP0278776B2 (en) 2004-04-14
IL85411A (en) 1994-07-31
DE3855921T2 (de) 1998-01-15
EP0787802A2 (en) 1997-08-06
ATE153696T1 (de) 1997-06-15
ATE298800T1 (de) 2005-07-15
EP0278776A3 (en) 1989-09-13
AU1170588A (en) 1988-08-18
DE3855921D1 (de) 1997-07-03
DE3856580T2 (de) 2006-05-24
ES2244989T3 (es) 2005-12-16
AU617302B2 (en) 1991-11-28
IE81149B1 (en) 2000-05-03
DE278776T1 (de) 1995-06-29
EP0278776A2 (en) 1988-08-17
JP2869920B2 (ja) 1999-03-10
EP0278776B1 (en) 1997-05-28
IE880380L (en) 1988-08-12
ES2068791T5 (es) 2004-12-16
EP0787802A3 (es) 1997-08-27
JPS63301797A (ja) 1988-12-08
DE3856580D1 (de) 2005-08-04
DE3855921T3 (de) 2005-03-10
NZ223506A (en) 1991-09-25

Similar Documents

Publication Publication Date Title
ES2068791T1 (es) Metodos y acido desoxirribonucleico para la preparacion de proteina de factor de tejido.
FI941245A (fi) Menetelmä 2'-deoksiguanosiinin asyylijohdannaisten valmistamiseksi
DK382786A (da) Overfladeaktivt rekombinant-alveolarprotein
KR880009035A (ko) Apc 폴리펩티드의 전구 단백질, 이를 위한 dna 암호화, 및 이 dna와 단백질의 진단 용도
EP1323824A3 (en) Use of human keratinocyte growth factor-2 for the preparation of pharmaceutical compositions
AU2742892A (en) An anticoagulant substance obtained from urine
MX9708528A (es) Quimiosina bata-13 humana.
NZ332318A (en) Chemokine alpha 2 and it's therapeutic and diagnostic use in treating illnesses
FI913818A0 (fi) Nytt trombolytiskt aemne.
ES2073391T3 (es) Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
FI952170A0 (fi) Koagulaatiota edistävää aktiivista ainetta sisältävä stabiili valmisteveren koagulaatiosairauksien hoitamiseksi
ATE300554T1 (de) Bindegewebe-wachstumsfaktor 3.
IT1246050B (it) Impiego dell'eptastigmina nella terapia dell'ictus cerebrale.
DK694287A (da) Overfladeaktivt rekombinant-alveolaerprotein
WO2001075008A3 (fr) Nouveau polypeptide, protéine hélicase-anneau-hélicase 11, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 278776

Country of ref document: ES